Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Alnylam Pharmaceuticals 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 USA

P: 617-551-8200 F: 617-551-8101

Description:

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Key Statistics

Overview:

Market Capitalization, $K 13,457,957
Shares Outstanding, K 111,490
Annual Sales, $ 74,910 K
Annual Net Income, $ -761,500 K
Last Quarter Sales, $ 70,060 K
Last Quarter Net Income, $ -208,540 K
60-Month Beta 2.46
% of Insider Shareholders 3.60%
% of Institutional Shareholders 95.79%
Float, K 107,476
% Float 96.40%

Growth:

1-Year Return 62.29%
3-Year Return 171.93%
5-Year Return 19.84%
5-Year Revenue Growth 58.81%
5-Year Earnings Growth -422.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.50 on 10/31/19
Next Earnings Date N/A
Earnings Per Share ttm -7.76
EPS Growth vs. Prev Qtr 4.95%
EPS Growth vs. Prev Year 20.99%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ALNY Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -12.15
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -52.88
Return-on-Assets (Before Tax) -37.14
Profit Margin % -1,016.55
Net Margin % -51.64
Debt/Equity 0.17
Price/Sales 184.20
Price/Cash Flow N/A
Price/Book 8.62
Book Value/Share 14.41
Interest Coverage N/A
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar